- Oral presentation
- Open Access
Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)
Journal of Translational Medicine volume 12, Article number: O7 (2014)
BRIM7 is a phase 1B study evaluating the safety and efficacy of combined BRAF and MEK inhibition with vemurafenib + cobimetinib. The utility of FDG-PET as an early predictor of clinical benefit was also evaluated in this study.
Materials and methods
Eligible patients (pts) had advanced BRAFV600-mutated melanoma and ECOG PS 0-1 and were either naïve to BRAF inhibitor (BRAFi-naïve) or had disease progression on vemurafenib (vem-progressor). Pts in the dose-escalation portion received vemurafenib 720 or 960 mg BID continuously and cobimetinib 60, 80, or 100 mg QD 14 days (d) on/14 d off (14/14); 21 d on/7 d off (21/7); or continuously (28/0). Two dose levels were expanded: vemurafenib (720 mg and 960 mg BID) + cobimetinib 60 mg QD 21/7. FDG-PET scans were performed at baseline and on Day 15 of Cycles 1 and 2. Correlation between tumor glucose metabolism changes, baseline tumor burden and target lesion responses were evaluated.
128 pts were treated with vemurafenib + cobimetinib as of 21 June 2013; male 60%, median age 55 y (19-88), stage M1c 76% and BRAFi-naive 49%. Median duration of follow-up in vem-progressor and BRAFi-naïve pts was 3 and 10 months, respectively. Most adverse events (AE) were mild to moderate in severity and vem-progressor pts reported fewer AEs compared to BRAFi-naïve pts. Most common AEs in BRAFi-naïve pts (n=63) were non-acneiform rash (89%), diarrhea (81%), photosensitivity/sunburn (70%), fatigue (67%) and liver test abnormality (59%). Most frequent grade ≥3 AEs in BRAFi-naïve pts were liver test abnormality (19%), non-acneiform rash (13%), arthralgia (11%) and fatigue (10%).
BRAFi-naive pts attained 85% confirmed response rate (RR), including 10% complete responses; median PFS was not reached at 10 months follow-up. Vem-progressor pts attained 15% confirmed RR, stable disease of 43%, and median PFS of 2.8 months. Preliminary FDG-PET analysis showed that the magnitude of reduction in tumor glucose uptake correlated with maximal tumor reduction, but the degree of correlation varied across time and in BRAFi-naïve and Vem-progressor pts.
Vemurafenib + cobimetinib can be safely administered at the respective single-agent MTDs of vemurafenib (960 mg BID) and cobimetinib (60 mg 21/7). Preliminary efficacy of the combination is encouraging in BRAFi-naive patients. FDG-PET is a potentially useful marker of early biologic response to the combination.
About this article
Cite this article
Puzanov, I., McArthur, G., Gonzalez, R. et al. Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7). J Transl Med 12, O7 (2014) doi:10.1186/1479-5876-12-S1-O7
- BRAF Inhibitor
- Liver Test Abnormality
- Tumor Glucose
- Tumor Glucose Metabolism